Rezolute (RZLT) Competitors

Spyre Therapeutics (NASDAQ:SYRE) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.

Is SYRE or RZLT more profitable?

Rezolute's return on equity of -70.27% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-210.01%	-44.40%
Rezolute	N/A	-70.27%	-62.41%

Do analysts prefer SYRE or RZLT?

Spyre Therapeutics currently has a consensus price target of $53.40, suggesting a potential upside of 246.75%. Rezolute has a consensus price target of $12.14, suggesting a potential upside of 207.41%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyre Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Rezolute	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Does the media refer more to SYRE or RZLT?

In the previous week, Rezolute had 15 more articles in the media than Spyre Therapeutics. MarketBeat recorded 20 mentions for Rezolute and 5 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.58 beat Rezolute's score of 0.55 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rezolute	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, SYRE or RZLT?

Spyre Therapeutics has a beta of 2.78, meaning that its share price is 178% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Do insiders & institutionals believe in SYRE or RZLT?

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 18.4% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor SYRE or RZLT?

Rezolute received 52 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 80.43% of users gave Rezolute an outperform vote.

Company	Underperform	Outperform
Spyre Therapeutics	Outperform Votes 22 100.00%	Underperform Votes No Votes
Rezolute	Outperform Votes 74 80.43%	Underperform Votes 18 19.57%

Which has better valuation & earnings, SYRE or RZLT?

Rezolute has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	1,042.98	-$338.79M	-$3.77	-4.08
Rezolute	N/A	N/A	-$68.46M	-$1.15	-3.43

Summary

Spyre Therapeutics beats Rezolute on 9 of the 16 factors compared between the two stocks.